438 related articles for article (PubMed ID: 26141860)
21. IL-6 promotes growth and epithelial-mesenchymal transition of CD133+ cells of non-small cell lung cancer.
Lee SO; Yang X; Duan S; Tsai Y; Strojny LR; Keng P; Chen Y
Oncotarget; 2016 Feb; 7(6):6626-38. PubMed ID: 26675547
[TBL] [Abstract][Full Text] [Related]
22. CCL21/CCR7 Axis Contributed to CD133+ Pancreatic Cancer Stem-Like Cell Metastasis via EMT and Erk/NF-κB Pathway.
Zhang L; Wang D; Li Y; Liu Y; Xie X; Wu Y; Zhou Y; Ren J; Zhang J; Zhu H; Su Z
PLoS One; 2016; 11(8):e0158529. PubMed ID: 27505247
[TBL] [Abstract][Full Text] [Related]
23. Clinical and biological significance of stem-like CD133(+)CXCR4(+) cells in esophageal squamous cell carcinoma.
Lu C; Xu F; Gu J; Yuan Y; Zhao G; Yu X; Ge D
J Thorac Cardiovasc Surg; 2015 Aug; 150(2):386-95. PubMed ID: 26092504
[TBL] [Abstract][Full Text] [Related]
24. Prognostic Value of the Stem Cell Markers Epcam and CD133 Expression Of Gallbladder Adenocarcinoma.
Jiang S; Pei L; Yang ZL; Liu G
Hepatogastroenterology; 2014 May; 61(131):574-9. PubMed ID: 26176038
[TBL] [Abstract][Full Text] [Related]
25. CXCR4 Inhibition Counteracts Immunosuppressive Properties of Metastatic NSCLC Stem Cells.
Fortunato O; Belisario DC; Compagno M; Giovinazzo F; Bracci C; Pastorino U; Horenstein A; Malavasi F; Ferracini R; Scala S; Sozzi G; Roz L; Roato I; Bertolini G
Front Immunol; 2020; 11():02168. PubMed ID: 33123122
[TBL] [Abstract][Full Text] [Related]
26. Context-dependent adaption of EpCAM expression in early systemic esophageal cancer.
Driemel C; Kremling H; Schumacher S; Will D; Wolters J; Lindenlauf N; Mack B; Baldus SA; Hoya V; Pietsch JM; Panagiotidou P; Raba K; Vay C; Vallböhmer D; Harréus U; Knoefel WT; Stoecklein NH; Gires O
Oncogene; 2014 Oct; 33(41):4904-15. PubMed ID: 24141784
[TBL] [Abstract][Full Text] [Related]
27. Clinical significance of stem cell marker CD133 expression in colorectal cancer.
Wang BB; Li ZJ; Zhang FF; Hou HT; Yu JK; Li F
Histol Histopathol; 2016 Mar; 31(3):299-306. PubMed ID: 26442717
[TBL] [Abstract][Full Text] [Related]
28. Prognostic value of cancer stem cells, epithelial-mesenchymal transition and circulating tumor cells in lung cancer.
Pirozzi G; Tirino V; Camerlingo R; La Rocca A; Martucci N; Scognamiglio G; Franco R; Cantile M; Normanno N; Rocco G
Oncol Rep; 2013 May; 29(5):1763-8. PubMed ID: 23426441
[TBL] [Abstract][Full Text] [Related]
29. Effect of EpCAM, CD44, CD133 and CD166 expression on patient survival in tumours of the ampulla of Vater.
Piscuoglio S; Lehmann FS; Zlobec I; Tornillo L; Dietmaier W; Hartmann A; Wünsch PH; Sessa F; Rümmele P; Baumhoer D; Terracciano LM
J Clin Pathol; 2012 Feb; 65(2):140-5. PubMed ID: 22130902
[TBL] [Abstract][Full Text] [Related]
30. The role of CD133 expression in the carcinogenesis and prognosis of patients with lung cancer.
Le H; Zeng F; Xu L; Liu X; Huang Y
Mol Med Rep; 2013 Nov; 8(5):1511-8. PubMed ID: 24008862
[TBL] [Abstract][Full Text] [Related]
31. Infiltrating bone marrow mesenchymal stem cells increase prostate cancer stem cell population and metastatic ability via secreting cytokines to suppress androgen receptor signaling.
Luo J; Ok Lee S; Liang L; Huang CK; Li L; Wen S; Chang C
Oncogene; 2014 May; 33(21):2768-78. PubMed ID: 23792449
[TBL] [Abstract][Full Text] [Related]
32. Differential expression of CXCR4 is associated with the metastatic potential of human non-small cell lung cancer cells.
Su L; Zhang J; Xu H; Wang Y; Chu Y; Liu R; Xiong S
Clin Cancer Res; 2005 Dec; 11(23):8273-80. PubMed ID: 16322285
[TBL] [Abstract][Full Text] [Related]
33. CD133+ ovarian cancer stem-like cells promote non-stem cancer cell metastasis via CCL5 induced epithelial-mesenchymal transition.
Long H; Xiang T; Qi W; Huang J; Chen J; He L; Liang Z; Guo B; Li Y; Xie R; Zhu B
Oncotarget; 2015 Mar; 6(8):5846-59. PubMed ID: 25788271
[TBL] [Abstract][Full Text] [Related]
34. Epigenetic regulation of CD133 and tumorigenicity of CD133+ ovarian cancer cells.
Baba T; Convery PA; Matsumura N; Whitaker RS; Kondoh E; Perry T; Huang Z; Bentley RC; Mori S; Fujii S; Marks JR; Berchuck A; Murphy SK
Oncogene; 2009 Jan; 28(2):209-18. PubMed ID: 18836486
[TBL] [Abstract][Full Text] [Related]
35. Cucurbitacin I inhibits tumorigenic ability and enhances radiochemosensitivity in nonsmall cell lung cancer-derived CD133-positive cells.
Hsu HS; Huang PI; Chang YL; Tzao C; Chen YW; Shih HC; Hung SC; Chen YC; Tseng LM; Chiou SH
Cancer; 2011 Jul; 117(13):2970-85. PubMed ID: 21225866
[TBL] [Abstract][Full Text] [Related]
36. Epithelial Mesenchymal Transition in Aggressive Lung Cancers.
Mittal V
Adv Exp Med Biol; 2016; 890():37-56. PubMed ID: 26703798
[TBL] [Abstract][Full Text] [Related]
37. CD133/Src axis mediates tumor initiating property and epithelial-mesenchymal transition of head and neck cancer.
Chen YS; Wu MJ; Huang CY; Lin SC; Chuang TH; Yu CC; Lo JF
PLoS One; 2011; 6(11):e28053. PubMed ID: 22140506
[TBL] [Abstract][Full Text] [Related]
38. Prognostic impact of the expression of putative cancer stem cell markers CD133, CD166, CD44s, EpCAM, and ALDH1 in colorectal cancer.
Lugli A; Iezzi G; Hostettler I; Muraro MG; Mele V; Tornillo L; Carafa V; Spagnoli G; Terracciano L; Zlobec I
Br J Cancer; 2010 Jul; 103(3):382-90. PubMed ID: 20606680
[TBL] [Abstract][Full Text] [Related]
39. Non-small cell lung cancer cells expressing CD44 are enriched for stem cell-like properties.
Leung EL; Fiscus RR; Tung JW; Tin VP; Cheng LC; Sihoe AD; Fink LM; Ma Y; Wong MP
PLoS One; 2010 Nov; 5(11):e14062. PubMed ID: 21124918
[TBL] [Abstract][Full Text] [Related]
40. Bmi-1 is essential for the oncogenic potential in CD133(+) human laryngeal cancer cells.
Wei X; He J; Wang J; Yang X; Ma B
Tumour Biol; 2015 Nov; 36(11):8931-42. PubMed ID: 26081615
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
